Compare S&P Global Inc (SPGI) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P Global Inc vs Viatris Inc — how do they compare? S&P Global Inc trades at $409.33 (market cap $120.48B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: S&P Global Inc is far larger — about 6.4× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| SPGI | VTRS | |
|---|---|---|
Market Cap | $120.48B | $18.69B |
Sector | Financials | Health |
52-Week High | $534.79 | $17.86 |
52-Week Low | $370.42 | $9.49 |
Enterprise Value | $131.97B | $30.80B |
Dividend Yield | 0.95% | 2.95% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
